The nucleic acid-binding proteins of bovine leukemia virus (BLV) and feline leukemia virus (FeLV) were isolated in a high state of purity with chloroformmethanol extraction followed by reversed-phase liquid chromatography. Selective solubilization and purity of BLV p12 and FeLV plO was confirmed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The compositions and molecular weights were determined by amino acid analysis. An abundance of lysine and arginine residues along with their size identifies both BLV p12 and FeLV plO as small basic proteins similar to well-defined type C viral nucleoproteins. NH2-terminal degradation by the semiautomated Edman method provided the sequence of the first 40 amino acids for both proteins. The putative nucleic acid binding site found in several type C viral nucleoproteins was contained within this sequence, with the most homology centered around an eight-amino acid region involving seven identical residues and one substitution. Antisera were developed in rabbits, and specificity and titers were determined by electroblotting and immunoautoradiography. By this technique, an immunological cross-reaction was found between BLV p12 and FeLV plO. The shared antigenic determinant most likely exists in the highly conserved eight-amino acid region. Although this sequence is also highly conserved in the nucleic acid-binding proteins of murine leukemia viruses, the shared antigenic determinant is not found in these or any other type C viruses tested. It is suggested that substitution of arginine (BLV pl2/FeLV p10) to lysine (murine leukemia virus p10) is sufficient to elicit a change in antibody specificity.
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MORGAN, COPELAND, AND OROSZLAN which are similar in properties to the proteins of MuLV. Based on protein sequence homology and immunological relatedness with MuLV, FeLV is classified as type C, subgroup I (23) .
The only BLV protein partially sequenced is p24, which is found to contain sequence homology with type C virus p30 structural proteins, especially with FeLV p27, suggesting that BLV p24 and FeLV p27 are evolutionarily related proteins (22) . BLV p24 has recently been found (25) to have structural homology with the analogous 24 ,000-molecular-weight protein from a virus associated with human adult T-cell leukemia-lymphoma and designated HTLV (26) . Several lines of evidence indicate that the NBPs of the virion may be among the most conserved gag gene products of retroviruses. As the RNAassociated internal core proteins of the virus, they may have an important function in replication and assembly and they may be under high evolutionary constraint. As a continuation of our studies on the BLV-FeLV relationship, we sequenced and immunologically characterized the NBPs of these viruses. The primary structure data of BLV p12 and FeLV plO show the presence of a highly conserved segment in the putative nucleic acid binding site region. This and the results of immunological analysis which indicate cross-reaction permit the delineation of the shared antigenic determinant.
MATERIALS AND METHODS Virus. BLV was grown in fetal lamb kidney cells (33) , and the Rickard strain (A, B) of FeLV was grown in feline lymphoblasts (27) . Viruses were purified by sucrose density gradient centrifugation according to standard procedures and obtained from the Viral Resources Laboratory of the National Cancer InstituteFrederick Cancer Research Facility, Frederick, Md.
Chloroform-methanol extraction. NBPs of BLV and FeLV were partially purified by chloroform-methanol extraction (21) . Chloroform-methanol (2:1, vol/vol) was added to the virus suspension in the presence of low-ionic-strength buffer, 0.01 M Tris-hydrochloride, pH 7.4)-0.001 M EDTA-0.05 M NaCl. After vigorous agitation for 2 min, the phases were separated by centrifugation at 2,000 rpm for 20 min at 4°C. The phosphoprotein and RNA partitioned to the aqueous phase, the viral lipids partitioned to the organic phase, and the remaining viral proteins were contained in the interphase. To solubilize BLV p12 and FeLV plO, the interphase was resuspended in high-ionic-strength buffer, 0.01 M Tris-hydrochloride (pH 7.4)-0.001 M EDTA-1.0 M NaCl, and the extraction was repeated with the NBP contained in the high-ionic-strength aqueous phase.
RPLC. Further purification was performed by reversed-phase liquid chromatography (RPLC) on a Waters > Bondapak C18 column (13) . The NBP contained in the aqueous phase from high-ionic-strength chloroform-methanol extraction was lyophilized and then resuspended in 6 M guanidine-HCl and adjusted to a pH of 2.0 with l1o trifluoroacetic acid. A 0 to 30%o gradient of acetonitrile in 0.05% trifluoroacetic acid at pH 2.0 was used to elute the NBP from the column by reduction of the hydrophobic interactions. Proteins were recovered by lyophilization.
Reduction and carboxanidomethylation. Protein was reduced in the presence of 6 M guanidine-HCI-0.1 M NaHCO3 (pH 8.5) buffer with 0.17 M dithiothreitol. Samples were flushed with N2 and incubated at room temperature for 3 h. Reduced proteins were carboxamidomethylated with 0.4 M iodoacetamide (room temperature; 13 to 14 h).
SDS-PAGE. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), according to the formulation of Laemmli (17) , was used to determine purity of the NBPs and approximate molecular weights.
Amino acid analysis. The composition and molecular weight of the NBPs were determined by amino acid analysis on a Durrum D500 amino acid analyzer as previously described (11) . The raw data were analyzed by a program run on the National Institutes of Health DEC 10 computer which selects a molecular weight for the protein based in such a way as to minimize the departure from integral values for all residues (3).
NH2-terminal sequence analysis. NH2-terminal sequence analysis by semiautomated Edman degradation was performed with the spinning-cup liquid phase system (24) on a Beckman 890C sequencer in the presence of Polybrene (30) . RPLC on a Waters phenylalkyl column was used to identify and quantitate the PTH derivatives of amino acids (10) .
Antisera. Antisera to the purified NBPs were developed in rabbits. The initial injection was made intradermally in the back footpads and subcutaneously in four sites on the hind of the rabbit with 150 ,ug of NBP in phosphate-buffered saline mixed with an equal volume of Freund complete adjuvant. The rabbits were boosted subcutaneously approximately every 10 days with 50 Fg of purified protein each time in phosphate-buffered saline mixed with an equal volume of Freund incomplete adjuvant. Ten days after the second boost, the first test bleed of 10 ml from the ear vein was obtained. The rabbits were repeatedly boosted and then bled according to this schedule. Animals immunized with BLV p12 and FeLV plO were bled out by heart puncture after 130 and 182 days, respectively. Anti-BLV p24 guinea pig serum and anti-FeLV p27 rabbit serum were available from previous studies (8) .
Electroblotting and lmmunoautoradlography. The specificities of the antisera were determined by electroblotting and immunoautoradiography (29) . BLV and FeLV were electrophoresed on 7.5 to 20%o SDSpolyacrylamide slab gels. After electrophoresis the gel was equilibrated in transfer buffer (0.04 M sodium phosphate, pH 6.5). Aminobenzyloxymethyl paper was converted to the active diazobenzyloxymethyl form (DBM paper) by treatment with freshly prepared 4 mM NaNO2 in 1.17 M HCI for 30 min on ice and then washed with water and equilibrated with transfer buffer. Virus was transferred from the gel to DBM paper electrophoretically for 2 h at 25 V. Remaining active groups on the paper were blocked after incubation at room temperature for 2 h with 1% bovine serum albumin in transfer buffer. The paper was rinsed in water and cut vertically into 0.5-cm-wide strips (representing a lane of separated viral proteins from SDS-PAGE) which were rotated at 37°C in rabbit antiserum DOT tests. Antibody titers were determined by directly spotting DBM paper strips with 1 Fg of purified NBP in 0.04 M sodium phosphate buffer, pH 6.5 . With this method an exact amount of protein was bound to DBM paper. Reaction with serial dilutions of antisera, 2'"I-labeled protein A, and autoradiography were carried out as described above.
RESULTS

Purification of BLV and FeLV NBPs. The
NBPs of BLV and FeLV were purified by chloroform-methanol extraction and RPLC. The proteins partitioned to the high-ionic-strength aqueous phase during extraction with chloroform-methanol. An approximate purity of >95% after chloroform-methanol extraction was determined by SDS-PAGE. RPLC was used to remove possible contaminating protein components and RNA and allow for desalting and rapid concentration of protein by lyophilization from a volatile solvent. RPLC profiles of the extracted proteins from BLV, FeLV, and reduced and carboxamidomethylated protein from BLV are shown in Fig. 1A , B, and C, respectively. Both nucleoproteins eluted at 25% acetonitrile as the major component of the extraction. The elution patterns of BLV and FeLV NBPs indicated multiple protein peaks (three) eluting within a narrow range of acetonitrile gradient. When BLV p12 was reduced and carboxamidomethylated the elution pattern showed a single major peak, suggesting that the apparent chromatographic heterogeneity may have been due to the formation of inter-or intramolecular S-S bonds.
The purity of the proteins and approximate molecular weights were determined by SDS-PAGE. Purified NBP from BLV is demonstrated in Fig. 2A . In our system it has an Mr of -8,000 compared with standard proteins. Previous nomenclature has identified this protein as BLV p12 (4). We will use the same designation. Figure 2B confirms the purity of FeLV p1O, the NBP from FeLV, which has a molecular weight of -6,000.
Amino acid composition. The amino acid compositional data of BLV p12 and FeLV p1O, based on 24-, 48-, and 72-h hydrolysis, are given in Table 1 . The total number of amino acids Fig. 3A . Assignments were based on the occurrence of a newly arising peak at each cycle compared with standard PTH amino acids. In a single microsequence analysis of 4 nmol of BLV p12, unambiguous assignments were made for residues 1 to 40 except cysteines in positions 24, 27 , and 37, leucine residue 28 (which was lost), and threonine 39. Cysteine residues cannot be identified after Edman degradation of the unmodified protein due to their instability. The cysteines were determined by degrading purified peptides derived by endoproteinase Lys-C cleavage of reduced and carboxamidomethylated BLV p12. degradation and also allowed assignments to be made at positions 28 and 39 as shown. Figure 3B shows the sequence for FeLV p1O. The first 40 amino acid residues, except cysteine residues 30 and 33 and lysine 27, were determined by a single microsequencing analysis of 12 nmol of protein. Assignments of the cysteines and lysine residue 27 were made as previously discussed for BLV p12, using Lys-C cleavage fragments (T. D. Copeland 
V H T P G P K M P G P R Q P A P * * * K R P P P G P * * schedules with the resulting antibody titers for BLV p12 and FeLV plO are shown in Fig. 5 . Arrows indicate days when injections (a total of nine for each rabbit) were made, and circles indicate the titers of test bleed and bleed-out sera. Each serum was titrated by immunoautoradiography, using the DOT test. The highest titers obtained for anti-BLV p12 serum, and FeLV plO antiserum were 16 taken before immunization of either rabbit were negative. Specificity of antisera to BLV p12 and FeLV plO was further studied by immunoautoradiography involving the electrotransfer of SDS-PAGE-separated viral proteins to DBM paper (Fig. 7) . In lanes 1 to 3 FeLV proteins were transferred and stained with appropriate antisera. Lane 1 shows the reaction with anti-FeLV p27 rabbit serum. Lane 2 was stained with antiFeLV plO rabbit serum which reacted with plO only. The same protein was also recognized by antiserum to BLV p12 as shown in lane 3. BLV proteins were transferred in lanes 4 to 6 and stained with appropriate antisera. Lane 4 shows the reaction of BLV with anti-BLV p24 guinea pig serum. Lane 5 was stained with anti-BLV p12 rabbit serum. Rabbit antiserum to FeLV plO also cross-reacted with BLV p12. Both antisera to BLV and FeLV NBPs reacted specifically with BLV, recognizing p12 only. Various other retroviruses were tested with anti-BLV p12 and anti-FeLV plO rabbit sera after virus proteins were transferred to DBM paper. Table 2 summarizes these results. As expected, anti-FeLV plO serum reacted in an interspecies fashion with other mammalian type C virus NPBs but not with Rous avian sarcoma virus p12. The anti-BLV p12 serum, however, did not recognize any type C virus tested except FeLV. Homologous and heterologous titers (numbers in parentheses) for both sera are also given in Table 2 .
DISCUSSION
Chloroform-methanol extraction and RPLC in combination are effective methods in which to purify to a high state of purity the NBPs of BLV and FeLV. The purity of BLV p12 and FeLV plO was confirmed by SDS-PAGE. In spite of the apparent homogeneity in this system, RPLC patterns indicated multiple protein peaks eluting within a narrow range of an acetonitrile gradient. This heterogeneity of chloroform-methanol-extracted BLV p12 was shown to be due to disulfide cross-links between cysteine residues. The reduced and carboxamidomethylated protein eluted as a single peak. It is assumed that similar intra-or intermolecular cysteine interactions may be responsible for the chromatographic heterogeneity of FeLV p1O. It is clear from the partial sequence data that both proteins have more than one cysteine.
The amino acid composition data indicate that both NBPs contain an abundance of basic amino acids. No amino acid appeared with higher residue number than lysine plus arginine in either protein except the 15 residues of proline found in BLV p12. This unusually high figure for proline in BLV p12 is not shared in the compositions of FeLV plO and of other known NBPs of type C viruses. Recently, the primary structure of the NBP (p1O) of R-MuLV was reported (12) . RMuLV plO is a basic protein containing 5 lysine, 9 arginine, and 2 histidine residues, a total of 16 basic amino acid residues of 56 in the complete protein. Gel filtration and electrophoretic analysis had originally estimated the molecular weight to be between 7,000 and 10,000. The exact molecular weight is reported as 6,347. The molecular weights calculated from composition (without cysteine and tryptophan) for BLV p12 (6, 034) and for FeLV plO (5, 652) except for proline in BLV p12 (see above), structurally defined MuLV viral NBP.
The alignments of FeLV p1O, BLV pl R-MuLV plO are shown in Fig. 4 . BLV pl FeLV plO NH2-terminal sequences do no tain much homology in the first 40 residi the proteins. The most homology betwee proteins centers around a common regioi contained in R-MuLV p1O. This conserv gion has been expressed as a set of thre residues spaced at N, N + 3, and N + 13 Gly-His sequence at N + 7 and N + 8, wh is the position in the amino acid sequence first Cys residue of the set (cysteine in pc 30 in the alignment). Involvement of ty: and lysine residues in nucleic acid binding; ty of proteins has been indicated with stud the chemical modification of R-MuL% (L. E. Henderson b Antiserum was used at 1:6,000 dilution in the homologous system and 1:100 in the heterologous systems.
c Antiserum dilutions were 1:10,000 in the homologous system and 1:100 in the heterologous systems.
d The numbers in parentheses represent the titers of bleed-out sera as determined by the DOT test.
VOL. 46, 1983 single amino acid difference between FeLV and BLV. Alanine of BLV p12 is substituted for valine in FeLV p10. In this position R-MuLV plO has alanine, like BLV p12. C-terminal to this residue, both bovine p12 and feline plO have arginine whereas the murine plO has lysine.
Since the complete amino acid sequence of BLV p12 (Copeland et show a higher degree of homology in the other parts of the molecules, the above eight-residue segment is the most likely candidate to represent the shared antigenic site responsible for BLV pl2/FeLV plO cross-reaction readily detectable on denatured proteins. The Ala-Val exchange may not be considered significant enough to alter the immunogenic response and subsequent antigen-antibody complexing. Although arginine and lysine are both basic amino acids, they are sterically different. This difference could explain why anti-BLV p12 serum reacts with FeLV plO but not with the murine p10. Chemical modification of arginine and lysine residues and the use of synthetic peptides will aid the accurate definition of the immunogenic determinant shared by BLV and FeLV.
